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Abstract  
Objective: Fatigue is an important outcome for patients with rheumatoid arthritis (RA).  The 
aim of this study was to identify the scales being used to measure RA fatigue, and 
systematically examine the evidence for their validation. 
Methods:  Articles measuring fatigue in RA were searched for using the terms RA and 
fatigue, and RA and tiredness, plus scale, questionnaire, inventory and checklist.  Index 
papers reporting identifiable RA fatigue data were examined for the fatigue scale used.  Index 
and validation papers for each scale were reviewed for evidence supporting scale validation 
to measure RA fatigue using a standardized checklist of content, face, criterion and construct 
validity, reliability and sensitivity to change. 
Results:  61 index papers used 23 different fatigue scales to measure RA fatigue on 71 
occasions.  Seventeen scales had either no data on validation in RA, or limited evidence.  
Reasonable evidence of validation was identified for 6 scales, each also having some 
evidence of sensitivity to change: Ordinal scales; the SF-36 vitality subscale; the Functional 
Assessment of Chronic Illness Therapy Fatigue Scale; Visual Analogue Scales, the Profile of 
Mood States, and the RA-specific Multi-dimensional Assessment of Fatigue scale.  However, 
the 4 generic scales would benefit from further validation in RA patients, the VAS requires 
standardization, and the MAF would benefit from further sensitivity data. 
Conclusion:  It was possible to identify evidence of reasonable validation for 6 out of 23 
scales being used to measure RA fatigue.  Researchers and clinicians should select scales to 
measure RA fatigue carefully.   
 3 
Background 
Rheumatoid arthritis (RA) is an auto-immune, systemic, inflammatory condition causing 
pain, disability and psychological distress.
1
  Fatigue is experienced by up to 90% of patients 
with RA and its causality is likely to be multi-dimensional.
2-4 
Fatigue has far-ranging 
consequences on patient’s lives and is an important outcome for many patients,5-8 but is 
currently not among the 7 internationally agreed core outcome measures in RA clinical 
trials.
9
  However, the OMERACT group (Outcome Measures in Rheumatology Clinical 
Trials) has been discussing the importance of fatigue as a key outcome and has given a 
mandate to pursue further work on identifying valid measures.
10
 
If treatments are to be developed and tested, fatigue needs to be accurately assessed using 
scales with adequate validation properties of comprehensiveness, accuracy, biological sense, 
reliability and sensitivity to change.  In common with many other chronic illnesses, there is 
no agreed definition of fatigue in RA.  However, it is widely accepted by clinicians that there 
is a subjective element to RA fatigue that goes beyond physiological muscle fatigue.  
Qualitative studies suggest RA fatigue may incorporate not only physical but also cognitive 
and emotional elements.
2,5  
The nature of fatigue as experienced by RA patients may be 
different to that in other long term conditions,
5
 therefore the application of generic scales, or 
the creation of new scales without patient involvement may have limited validity.  Generic 
scales may contain items that in RA could reflect inflammatory disease or disability rather 
than fatigue (as seen in some generic depression scales).
11
   
The use of inappropriate or unvalidated scales for outcomes can result in unreliable or 
misleading results.  The Association of Rheumatology Health Professionals (ARHP) has 
recently reviewed a wide range of arthritis measurement scales but this extensive and 
valuable resource was of necessity limited by space constraints and was not intended to 
examine the specific validity for scales to measure RA fatigue.
12
  The aim of the present 
 4 
study was therefore to systematically identify scales that have been used to measure fatigue in 
RA in published studies, and examine the evidence for their validity to measure RA fatigue 
against recognized criteria.
12-14
  
Methods 
Systematic identification of scales:  A systematic search for articles was undertaken to 
identify all the fatigue scales that are being used in RA.  In the absence of an internationally 
agreed definition of RA fatigue, the two global descriptors ‘fatigue’ and ‘tiredness’ were used 
in conjunction with ‘rheumatoid arthritis’.  Searches were performed for both alongside 1) 
scale, 2) questionnaire, 3) inventory and 4) checklist (keywords, English language).  These 8 
searches were applied to 5 databases:  Medline (Medicine, Dentistry and Nursing) from 1966, 
EMBASE (Medical) and PsychINFO (Psychology) from 1980, CINHAL (Cumulative Index 
to Allied Nursing and Health) from 1982, and AMED (Allied and Complementary Medicine 
Database) from 1985 (final search date 9
th
 February 2004).  The ‘grey’ literature of 
unpublished work was not searched as it has been shown to add little of value, and the studies 
may be of lesser quality.
15
   
Two researchers (SH, MH) independently reviewed all abstracts for the inclusion criteria of 
identifiable RA fatigue data.  All abstracts fitting these criteria were retained, plus any 
abstracts where it was unclear.  The full papers of these selected abstracts were obtained 
(index papers) and reviewed to identify the fatigue scales used.  Having systematically 
attempted to identify the fatigue scales being used in RA, information on their validation for 
use with RA patients was sought by reviewing the data in the index papers, data in the 
validation papers cited in the methods section of the index papers, and from any relevant 
references listed in the index and validation papers.  For 6 scales that showed reasonable 
validity for measuring RA fatigue, the databases were later searched again for additional 
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validation data in RA using the term rheumatoid arthritis and the scale name (final search 
date 17 January 2005).   
Evaluation of validation of scales:  Index and validation papers for each scale were reviewed 
independently (SH, JK, MH) for evidence supporting scale validation to measure fatigue in 
RA and where further validation papers were referenced these were also obtained and 
reviewed.  Evidence for face, content, criterion, and construct validity, reliability (internal 
consistency and stability) and sensitivity to change, was assessed using a checklist based on 
the methods of Katz,
12
 Tugwell and Bombardier
13 
and the added OMERACT filter of 
feasibility.
14
  The parameters for judging scale  validity are presented in Table 1.  Construct 
validity aimed to look for moderate associations with appropriate variables (eg pain, mood) 
but not strong associations as this might reflect an inability of the scale to differentiate 
between fatigue and these variables.  Criterion validity was assessed when there was 
comparison with any other RA fatigue measure, as there is no agreed ‘gold standard’ RA 
fatigue measure.  After independent assessments using this standardized approach (Table 1), 
the three assessors discussed their findings and, taking all the papers relating to each scale 
into account, scored each scale as to the strength of the available evidence for each of the 
validation concepts, to produce validation summaries (0 = not reported or no evidence, 1 = 
limited evidence, 2 = moderate, 3 = good).  Some instruments were well-validated generic 
fatigue scales, but were assessed specifically for their evidence that the scale was valid for 
measuring fatigue in RA.   
Results 
The searches identified abstracts from 166 initial papers containing the search terms, 59 of 
which it appeared might provide separately identifiable RA fatigue data in the full paper.  
Two further RA fatigue papers known to the authors were not identified by the searches (one 
used a scale acronym rather than the word ‘scale,’ one did not mention fatigue in the 
 6 
abstract), giving a total of 61 index papers.  Upon review of the full articles, 50/61 index 
papers reported identifiable RA fatigue data.  Twenty-three different fatigue scales were used 
with some studies utilizing more than one scale, giving 71 occasions on which fatigue was 
measured (Table 2).  Validation references were cited on only 35 occasions (49%).  Overall, 
118 papers were reviewed in the search for validation data, but only papers contributing 
substantial evidence are reported here. 
Fatigue scales where limited evidence of validation for RA could be identified: 
On systematic examination of the available validation data, for 7 out of the 23 scales being 
used to measure fatigue in RA either few validation studies could be identified, or evidence 
of validation was limited, or the scales had been designed for use in other populations and did 
not perform well in RA (Table 3).   
Seven scales had been created for single RA studies and did not appear to have previously 
been validated (Table 3).  Binary questions can only indicate the presence or absence of 
fatigue although they may be useful as a screening question.
16,17
  A measure of ‘Fatigue 
hours’ is sensitive to change in a randomized trial of NSAIDs, but the paper does not describe 
the question nor provide validity or reliability data.
18
  The ‘Five items modeled after Tack’ 
scale suggests evidence of sensitivity to change in a cognitive-behavioural therapy 
intervention (CBT) but no criterion or reliability data are provided.
19
  The Morning Fatigue 
scale
20
 may reflect the patient’s experience of waking unrefreshed5 but no validation data is 
provided.  Numerical rating scales have some evidence of construct validity but no data were 
identified on criterion validity, reliability or sensitivity.
6,21
 
Eight generic scales used to measure fatigue had limited data on validation in RA (Table 3).  
Some scales had been designed to measure cognition or personality.  For example, three of 
the 11 items on the Chalder Fatigue Scale (CFS) address mental clarity,
22
 and the scale does 
not differentiate between RA patients and controls.
23
  Three of the 8 items on the Checklist of 
 7 
Individual Strengths Subjective Fatigue subscale (CIS/SF) may reflect inflammation rather 
than fatigue (feeling fit, in good shape, in bad condition).
24-26
  The CIS/SF demonstrates 
sensitivity to change in its single study with RA patients undergoing CBT
27
 but has not been 
tested for reliability, construct or criterion validity in RA.  The Chronic Fatigue Index (CFI) 
was developed from interviews in chronic disease and reviewed by women with RA, showing 
content validity.  However, it was not re-tested after item reduction, and little evidence of 
testing for sensitivity, construct or criterion validity could be identified.
28
  The Composite 
Index of Fatigue Impairment (CIFI) is an 11 point numerical rating scale plus the Nottingham 
Health Profile energy subscale, but how these are combined is not explained,
29
 and the 
validation reference cited is inappropriate.  The Feeling Tone Checklist (FTC) was validated 
in healthy airforce personnel in 1956, which limits its applicability to RA fatigue, while the 
single RA study which tested it alongside an activity record, does not report any data 
(validation reference and scale unobtainable).
30
 
Generic fatigue scales can include items that might lead to contamination in RA from 
outcomes such as disability.  The Multi-dimensional Fatigue Inventory (MFI) contains such 
items (‘Physically I feel only able to do a little,’ ‘Physically I am in bad condition’).31  It does 
not differentiate between people with RA and ankylosing spondylitis on four of its 5 scales,
32
 
nor between RA patients and healthy controls on two.
33
  The Nottingham Health Profile 
(NHP) is a well-validated tool for surveying population health
34
 and although RA studies 
show the energy subscale has construct validity, stability and differentiates between RA and 
other populations, sensitivity to change and internal consistency have not been thoroughly 
examined in RA.
23,35-39
  The 3 item energy subscale contains one item on fatigue, the second 
concerns energy (an absence of fatigue may not translate to the presence of energy) and the 
third concerns effort, which in RA may be the result of disability.  The Psychasthenia scale is 
 8 
a personality scale and only 3/10 items assess physical fatigue.  Whilst it differentiates 
between RA and fibromyalgia patients, no other validation data could be identified.
40
 
Two RA-specific scales have limited data on validation.  The National Institutes of Health 
Activity Record (NIH ACTRE) was developed to measure outcomes of an energy 
conservation programme and is reported as having no standard scoring system and did not 
show sensitivity to change.
30,41
  The ‘Time to onset of fatigue’ question showed that fatigue 
did not improve in an NSAID trial but little information on construct or criterion validity 
could be found.
42,43
 
Only two of these 17 scales have evidence for stability in RA or have been tested against 
another fatigue measure and only 5 have been used in RA intervention studies.  On the 
limited evidence available to date, it seems uncertain whether the 17 scales in Table 3 would 
be the first choice for providing robust, valid, accurate and sensitive measures of fatigue in 
patients with RA. 
Scales with reasonable evidence of validation for measuring fatigue in RA 
Multi-dimensional Assessment of Fatigue scale (MAF):  The MAF comprises 16 questions 
concerning the quantity, degree, distress, impact and timing of fatigue.
44
  Questions 1-15 
form the final score (Global Fatigue Index, 0-50) while question 16 concerns change over the 
past week.  Questions 1-14 are 10 point items, while 15 and 16 are four point items.  The 
MAF is an RA-specific revision of the Piper Fatigue Scale developed in oncology, giving it 
face and content validity (Table 4) and it has been tested against another fatigue scale.
44,45
  
Construct validity is shown through moderate convergence with disease activity and mood 
(0.45-0.54).
44
  Higher MAF scores are related to increased depression and reduced sleep, with 
61% of variance in fatigue explained by disease activity, gender and psychosocial status.
44,46
  
Higher MAF scores differentiate between RA patients with and without previous depression, 
between different levels of disease activity and between patients and controls.
44,47-49
  
 9 
Reliability is reflected by good internal consistency (inter-item correlations 0.53-0.83; 
Cronbachs alpha 0.91-0.96).
44,46-48
  Sensitivity to change is shown following drug therapy
50
 
and after exercise, where the MAF showed initial worsening of fatigue followed by 
improvement beyond baseline, and showed a difference between low and high exercisers.
45
  
Although designed to be scored as a global fatigue scale, there is some evidence for the 
validity of the individual sections of the MAF.
44,45
 
Functional Assessment of Chronic Illness Therapy fatigue scale (FACIT-F):  The index 
paper using the FACIT in RA did not report fatigue data.
51
  The paper reporting RA 
validation was published shortly after the final search date but is nonetheless reviewed here.
52
  
The FACIT-F is a 13 item scale originally developed to measure fatigue in cancer 
patients.
53,54
 In RA, the FACIT-F shows convergent validity with disease activity, good 
internal consistency (cronbach’s alpha 0.86-0.87), and evidence of sensitivity to change 
(effect size 0.19-1.13).
52
  However, no information on divergent validity nor stability in RA is 
reported.  The source of the scale items was oncology patients and in RA, several items may 
be confounded by disability (eg needing help to do usual activities).  One item measures 
energy rather than fatigue and items applicable to cancer patients may hold less relevance for 
RA patients, for example feeling too tired to eat is not reported in qualitative RA fatigue 
studies.
2,5
 
Ordinal scales:  Three studies measured RA fatigue using ordinal scales such as ‘none’ to 
‘very severe’ with responses ranging from 4-7 points.6,55,56  Overall, ordinal scales showed 
reasonable content and construct validity (Table 4), differentiating between RA patients with 
and without inflammation, and showing association with other symptoms, reduced perceived 
ability to cope with fatigue, and poor sleep.
 6,55,56
  When measured 7 times per day over 7 
days, the ordinal scale appeared stable, and consistently showed fatigue was least at noon and 
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worst in the evenings, supporting the ability of ordinal scales to capture variation in fatigue.
55
  
However, there is no data from intervention studies. 
Profile of Mood States (POMS):  The POMS
57
 fatigue/inertia scale contains 7 items (worn 
out, listless, fatigued, exhausted, sluggish, weary, bushed).  It was designed to measure mood, 
but may address some of the cognitive elements and overwhelming fatigue raised by RA 
patients.
5
  The POMS has criterion validity in RA (MAF r=0.84),
48
 although little 
information on construct validity could be identified.  The POMS differentiates between RA 
patients with and without a fear of falling and has good internal consistency (cronbach’s 
alpha 0.88).
58
  Three dance or exercise-based interventions showed change in POMS, 
although this only approached significance
45,59,60 
while in one of these the MAF did show 
significant change.
45
 
SF-36 Vitality subscale:  The vitality subscale of the SF-36 comprises 4 items (full of life, 
energy, worn out, tired) with 6 responses from ‘all’ to ‘none of the time.61  Many studies 
report RA data.
52,61-75  
Three studies report RA patients have less vitality than healthy 
controls, suggesting good construct validity,
23,66,67
 but another study reports RA patients have 
more vitality than controls.
63
  Although the vitality scale is associated with measures of 
disease activity, correlations with ESR vary (r=0.18-0.34) and the vitality scale does not 
always reflect change in ESR.
62,65,67
  The SF-36 vitality subscale is shown to correlate 
strongly with mood in one study (r=0.67)
65
 suggesting it may not differentiate well between 
fatigue and depression.  The SF36 shows good internal consistency (Cronbach’s alpha 0.84-
0.88) and only a small ceiling and floor effect (Table 4).
63-65,72
  Sensitivity to change is shown 
with biologic agents (effect size 0.25-1.52).
52,68
   
Visual Analogue Scales:  VAS with identifiable RA fatigue data were used in 22 index 
papers and 4 times in papers obtained during the search for validation data.
3,23,74-96
  
Validation references for a fatigue VAS were cited on only 4/26 occasions and referred to 
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overviews of the ability of VAS to measure pain.
97  
Only 10/26 VAS were described 
sufficiently for them to be fully reproduced and only 3 could be identified as completely 
identical for descriptors, timescale and length (Table 5).  Lack of standardization clearly 
limits comparison between studies.   
Where the scales were described, VAS face and content validity were good (Table 6) except 
that information was rarely given as to whether patients were the source of the descriptors.  
Construct validity is reasonable with evidence of convergent validity with pain (r=0.31-0.8), 
poor sleep (r=0.6) and disability (r=0.33-0.41).
77,79,80,88
  VAS fatigue is moderately associated 
with low mood (r=0.41-0.47).
77,80,84
  VAS for fatigue discriminate between patients with RA 
and fibromyalgia, RA patients and healthy controls, and RA patients with and without 
pain.
23,76,79,91,92
  Overall, available evidence for reliability is limited, with one study showing 
stability for the VAS but not the SF-36, and another showing the opposite.
89,90
  Of 3 
intervention studies, one only reported combined OA/RA data,
86
 and neither total hip 
replacement
88
 nor an energy conservation program
96
 showed change in RA fatigue.  Three 
longitudinal studies show variation in a fatigue VAS over time.
87,89,90
 
One paper using a VAS to measure fatigue stated that for scanning purposes, it was formatted 
as 21 boxes representing a 0-10 scale in 0.5 increments (ClinHAQ).
98
 The reduction of a 
continuous VAS line to a tick-box scale of 21 discrete points may alter its measurement 
properties.  It is not stated in their earlier VAS studies whether it was presented in box or 
standard VAS format.
3,82,83
 
Some studies used several scales simultaneously.  A comparison of the VAS, MAF and SF36 
vitality subscale in a large RA cohort yielded mean scores of 4.5, 5 and 5.5 (out of 10).
98
  The 
scales correlated well with each other (r=0.71-0.8) and moderately with clinical measures 
(r=0.5-0.63).  The MAF had the smallest floor and ceiling effects at 0.01% and 0.2% (SF36 
0.4% and 3.4%; VAS 6.4% and 1.8%).  The VAS had the most variability with a SE of 0.032 
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(MAF and SF36, 0.026).  However, the VAS was presented as 21 boxes, the MAF and SF36 
were rescaled, and associations with mood were not assessed.   
Other studies reporting data from both a fatigue VAS and the SF36 vitality subscale show 
slightly lower associations (r=-0.58 to –0.71) and suggest the scales have different 
distributions and behave differently.
80,89,90
  The SF36 vitality subscale was more strongly 
associated with social and mental health, and unlike the fatigue VAS, varied with age.  
Although one longitudinal study suggested the SF36 and VAS change in similar ways,
87
 other 
studies report that changes in fatigue were sometimes shown on the VAS but not the SF36, 
and vice versa.
89,90
  These differences may reflect the conceptual gap between measuring 
fatigue and vitality, as a low score on one may not necessarily reflect a high score on the 
other.  
Discussion 
The use of poorly validated outcome scales would limit the interpretation of study results, yet 
this systematic review of scales used to measure RA fatigue shows that for 17 of the 23 scales  
used, only limited validation could be identified.  Many had been created for use in a single 
study, while for many others, little evidence of attempts at validation in RA could be found.   
Some of these scales for measuring RA fatigue may be useful and appropriate, but in the 
absence of identifiable validation data this is difficult to assess.  The MAF, SF36, FACIT-F, 
ordinal scales, POMS and VAS do show evidence of validation for measuring RA fatigue.  
However, even these 6 scales could benefit from further research, particularly into content 
validity for RA patients, the inclusion of cognitive items, and sensitivity to change. 
This study raises several important issues.  First, if authors do not give a validation reference 
for a scale, or do not fully describe it, it is difficult for readers to assess or replicate their 
methodology.  This is particularly problematic with the VAS where only 10/26 papers fully 
described the wording, timescale and length.  Whilst the combined data from many RA 
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studies supports reasonable validation for a fatigue VAS, there is no standardized VAS for 
RA fatigue, making comparison between studies difficult.  The most common VAS wording 
was ‘problem’ but this infers a combination of severity and consequence rather than pure 
level of fatigue.  There is a pressing need to develop and validate a standardized RA fatigue 
VAS.   
Second, many of these scales were developed ahead of the current systematic, rigorous 
approach to reporting validation data, making it difficult to assess their validation.  In 
particular, the inclusion of patient opinion into scale development is now considered crucial.  
The lack of sensitivity to change data is a major drawback, and is complicated by the lack of 
knowledge about which interventions might reduce RA fatigue.  A circular argument 
develops whereby it is difficult to validate scales for sensitivity until there are effective 
interventions, and it is difficult to prove efficacy of interventions without validated scales.  In 
RA, it is possible that interventions such as exercise may not improve fatigue, but they may 
allow patients to do more without increasing fatigue, an additional complication.  If future 
intervention studies could simultaneously measure other aspects of change, such as changing 
levels of activity or impact of fatigue, this might help clarify a difficult area. 
Third, some generic scales could be open to contamination as in RA the wording may reflect 
problems arising from disability or inflammation rather than fatigue.  Some scales include 
phrases that are not reflected in qualitative studies of the nature of RA fatigue (eg being too 
tired to eat) and most omit concepts that may be specific to RA fatigue (eg sudden, 
overwhelming onset, or cognitive elements).
2,5
  Several scales measure energy or vitality, but 
an absence of fatigue does not necessarily mean the presence of energy, therefore such scales 
may not accurately reflect fatigue.  Indeed, the POMS treats fatigue and vigor as different 
concepts and shows they are only moderately associated (r=0.43) and behave differently in 
their relationships with mood, suggesting they are not opposite ends of a single concept.
57
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This study has limitations, which include the lack of an internationally agreed definition of 
RA fatigue, which is outside the scope of this study.  Searching databases for RA and 
fatigue/tiredness produced an unmanageable dataset, therefore as the aim of the study was to 
identify fatigue measures, the terms scale, questionnaire, inventory and checklist where used.  
It is therefore possible some RA fatigue studies were missed that might have contributed 
validation data.  However a second search was conducted specifically for the measurement of 
RA fatigue using the 6 scales identified as having stronger validation.  The review scoring 
system was relatively arbitrary but the aim was to create a broad summary of available 
evidence, using criteria based on a recognized validation framework,
12-14
 systematically 
applied by three researchers first independently and then in discussion, to arrive at agreement.   
The treatment and self-management of fatigue in RA is receiving increasing interest as its 
importance to patients becomes apparent and this requires accurate measurement of fatigue.  
This study helps clarify a difficult issue by identifying stronger validation in certain fatigue 
scales.  However it also indicates that further work is urgently required to develop and 
validate a standardized VAS, to consider the addition of cognitive fatigue items to the MAF, 
to compare questionnaire items to qualitative descriptions of RA fatigue to ensure they 
capture the essence of the concept in RA, and to provide more sensitivity to change data for 
several scales.  A measure of the impact of fatigue, in addition to the presence or severity of 
fatigue would be useful. 
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Table 1:  Validation checklist 
 
Concept Questions Expectation of a good RA fatigue scale 
Validity 
    Face validity 
    Content validity 
 
 
    Criterion validity 
    Construct validity 
 
Reliability 
    Internal consistency 
    Stability 
Sensitivity to change 
Feasibility 
 
 
Does the method appear sensible? 
Is the source of the questions patient-based? 
Are all appropriate items included? 
Are misleading items avoided? 
Is it compared to a ‘gold’ standard measure? 
Does it show convergence with appropriate variables? 
Does it show divergence between different groups? 
 
Is it internally consistent (multi-item scales only) 
Is the scale stable? 
Is it sensitive to change? 
How long does it take to complete? 
Is it self-report or interviewer administered? 
How easy is it to score and interpret? 
 
Language reflects patients’ ideas of fatigue in RA2,5 
Evidence of patients as source or reviewer of items 
Eg physical, emotional, cognitive, consequence, severity 
Eg no items that might be confounded/confused with disability 
Tested against another fatigue scale 
Eg moderate correlation with pain, inflammation, mood, anaemia 
Eg between active/non-active disease; or RA patients/controls 
 
Inter-item correlation moderate or strong 
Unchanged in stable patients 
Changes after intervention (eg drugs, surgery, exercise, education) 
10-15 minutes maximum 
Self-report, as appropriate for subjective scale 
Clear instructions, or accessible computer programme/manual 
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Table 2 Fatigue scales identified as used in RA  
    RA studies 
Scale and subscale Acronym Description References reviewed Obs
1
 Int
2
 
Binary question:  Fatigue  Yes/No 16 1  
Binary question:  Tiredness  Yes/No 17 1  
Chalder Fatigue Scale CFS 11 items, 4 points 22, 23 1  
Checklist Individual Strengths: Subjective Fatigue CIS/SF 8 items, 7 points 24-27  1 
Chronic Fatigue Index CFI 16 VAS (mean) 28 1  
Composite Index Fatigue Impairment CIFI 11 point scale + NHP fatigue items 29 1  
Fatigue hours  Unknown  18  1 
Feeling Tone Checklist FTC 10 descriptors, unobtainable 30 1  
Five items modelled after Tack  Mean of 5 items 19  1 
Functional Assessment of Chronic Illness Therapy: 
     Fatigue scale 
FACIT-F 13 items, rated 0-4 51-54  1 
Morning fatigue  Lack vigour / fatigued on waking 20 1  
Multidimensional Assessment of Fatigue MAF 15 items plus change question 44-50 5 3 
Multidimensional Fatigue Inventory MFI 5 scales of 4 items.  5 points 31-33 2  
National Institutes of Health Activity Record  NIH ACTRE Log every 30 mins x 48 hours (0-4) 30, 41 1 1 
Nottingham Health Profile:  Energy subscale NHP 3 weighted items 23, 34-39  6  
Numerical Rating Scale: Degree  0-5 21 1  
Numerical Rating Scale:  Impact  0-10 6 1  
Ordinal degree scales*  Eg None, mild, moderate, severe  6, 55, 56, 3  
Profile of Mood States:  Fatigue/inertia subscale POMS 7 items 44-46, 57-60 3 3 
Psychasthenia  10 items 40 1  
Short Form 36 Health Survey:  Vitality Subscale SF36 4 items  23, 52, 61-75, 80, 87, 
89, 90 
16 5 
 
Time to onset of fatigue  Hours 42, 43 1 1 
Visual Analogue Scales VAS See table 5 3, 23, 74-97 23 3 
 
1Observational studies, 2Intervention studies 
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Table 3:  Scales currently used to measure fatigue in RA:  Little or limited evidence of validity 
 Validity  Reliability   
Feasible Face Content Criterion Construct     
 
 
Scale & subscale 
 
 
 
 
Source 
 
 
Inclusive 
No  
Misleading 
items 
 
‘Gold’ 
standard 
 
 
Converge 
 
 
Diverge 
  
Internal  
consistency 
 
 
Stability Sensitivity Feasibility 
Created for single study             
  Binary:  Fatigue 3 1 3 3 0 0 0  NA 0 0 3 
  Binary:  Tired 1 0 1 1 0 0 1  NA 0 0 3 
  Fatigue hours 0 0 0 0 0 0 0  NA 0 2 3 
  5 Items after Tack 1 1 2 2 0 1 0  0 0 2 2 
  Morning Fatigue 1 0 2 1 0 0 1  NA 0 0 3 
  Numerical Degree 3 0 3 3 0 1 0  NA 0 0 3 
  Numerical Impact 3 0 1 3 0 1 0  NA 0 0 3 
             
Scales applied in RA             
  CFS: Physical   3 2 3 2 1.5 0 1.5  0 0 0 3 
 Mental 3 2 3 2 1 0 1  0 0 0 3 
  CIS/SF 2 0 2 1 0 0 0  0 0 3 2 
  CFI Total 2 2 3 2 0 1.5 0  1.5 0 0 2 
    CFI Chronicity 3 2 3 3 0 0 0  1.5 0 0 0 
    CFI Interference 1 2 1 1 0 0 0  1.5 0 0 0 
  CIFI 0 0 0 0 0 2.5 0  0 0 0 0 
  FTC 0 0 0 0 0 0 0  0 0 0 2 
  MFI General  3 2 3 2 0 1.5 1.5  0 0 0 3 
 Physical 1 2 1 1 0 1.5 1.5  0 0 0 3 
 Activity 1 2 1 1 0 1.5 1.5  0 0 0 3 
 Motivation 1 2 1 1 0 1 1  0 0 0 3 
 Mental 2 2 2 2 0 1 1  0 0 0 3 
  NHP:  Energy 2 2 1 2 0 2 1.5  1 1.5 0 2 
  Psychasthenia 2 1 1 1 0 0 1  0 0 0 3 
             
RA-specific scales             
  NIH ACTRE 1 0 1 3 0 1 0  0 0 1 1 
  Time to onset 1 1 1 1 0 0 0  NA 1 1 3 
0 = Not reported/No evidence, 1 = Poor or limited evidence, 2 = Moderate evidence, 3 = Good evidence 
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Table 4:  Scales currently used to measure fatigue in RA:  Reasonable or good evidence of validity 
 Validity  Reliability   
 Face Content Criterion Construct      
 
Scale  
 
 
 
 
Source 
 
 
Inclusive 
No  
misleading 
items 
 
‘Gold’ 
standard 
 
 
Converge 
 
 
Diverge 
  
Internal  
consistency 
 
 
Stability 
 
 
Sensitivity 
 
 
Feasibility 
MAF:    Global Fatigue Index  3 2 2.5 3 2 2.5 2.5  3 1 3 3 
FACIT-F 2 1 2.5 1 2 2 0  3 0 2.5 2 
Ordinal scales: Best scores 3 0 3 3 0 1 2  NA 2 3 3 
  Stone:   Not at all-extremely 3 0 3 3 0 1 2  NA 2 3 3 
  Katz:  None-v severe 
*
 2 0 3 3 0 1 0  NA 0 0 3 
  Pinals:  None-severe  2 0 3 3 0 1 0  NA 0 0 3 
POMS:  Fatigue/inertia 2 2 2 2 1.5 0 1  3 0 1.5 1 
SF36: 
  Vitality (month) 
 
2 
 
1 
 
2 
 
2 
 
2 
 
2 
 
2 
  
3 
 
0 
 
3 
 
3 
  Vitality (week) 2 1 2 2 0 2 0  2 0 1 3 
 
*
Scores dichotomized in paper    
0 = Not reported/No evidence, 1 = Poor or limited evidence, 2 = Moderate evidence, 3 = Good evidence 
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Table 5:  Visual analogue scales currently used to measure fatigue in RA patients 
VAS Start descriptor End descriptor Timescale Length Scoring Comment in paper 
Lwin,
23
Gilboe
74,75
 No fatigue Fatigue as bad as it could be Month 100 mm 0-100  
Currey
76
 Fatigue is no problem Fatigue is a major problem Week 10 cm 0-10 Unusual fatigue or tiredness 
Tack
77
 No fatigue Fatigue as bad as it could be Week 100 mm 0-100  
Tack
77
 No distress Distress as bad as it could be Week 100 mm 0-100 Fatigue distress 
Scharloo
78
 No tiredness Very severe tiredness Week 10 cm 0-100  
Mengshoel
79
 No fatigue Total exhaustion Week 100 mm 0-100  
Kvien
80
 Fatigue no problem Fatigue major problem Month 100 mm 0-100  
Crosby
81
 No fatigue Extremely fatigued Evening before 10 cm  0-100% Vertical line 
Wolfe
3,82,83
 Fatigue no problem Fatigue major problem Week  - 0-3 Fatigue or tiredness  
Riemsma
84,85
 Not tired at all Very tired Week - 0-100  
Barlow
86
 No fatigue Fatigue as bad as it could be - 10 cm 0-10  
Hagen
87
 Fatigue is no problem Fatigue is a major problem - 100 mm   
Borstlap
88
 - - - - 0-10 Fatigue 
Brekke
89,90
 - - - 100 mm 0-100 Fatigue 
Gudbjornsson
91
 - - Time of investigation - 10 grades Degree of fatigue 
Heiberg
92
 - - - 100 mm 0-100 Fatigue 
Jensen
93
 - - - 100 mm 0-100 Fatigue 
Uhlig
94
 - - - 100 mm 0-100 Fatigue 
Chiang
95
 - - - 15 cm 0-150 Degree of fatigue 
Gerber
96
 - - - - 0-3  
 
- Data not supplied in paper 
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Table 6:  Validation of Visual Analogue Scales for measuring fatigue in RA:  Best scores for each version 
 Validity  Reliability   
 Face Content Criterion  Construct     
   
 
Source 
 
 
Inclusive 
No  
misleading 
items 
 
‘Gold’ 
standard 
  
 
Converge 
 
 
Diverge 
  
 
Stabilitye 
 
 
Sensitivity 
 
 
Feasibility 
Best scores overall 3 2 3 3 2  2.5 2.5  0 1.5 3 
             
Barlow
86
 3 0 2 3 0  0 1  0 0 1 
Borstlap
88
 0 0 0 0 0  2 1  0 0 0 
Brekke
89,90
 0 0 0 0 1  0 0  0 1.5 0 
Chiang
95
 0 0 0 0 0  0 0  0 0 0 
Crosby
81
 2 0 1 3 0  2 1  0 0 3 
Currey
76
 2 0 3 1.5 0  0 1.5  0 0 3 
Gerber
96
 0 0 0 0 0  0 0  0 0 0 
Lwin,
23
 Gilboe
74,75
 3 0 2 3 1  0 1  0 0 3 
Gudbjornsson
91
  2 0 2 3 0  0 2  0 0 2 
Hagen
87
 2.5 0 3 2.5 1  1 0  0 0 1 
Jensen
93
  0 0 0 0 0  0 1  0 0 0 
Heidberg
92
 0 0 0 0 1  0 0  0 0 0 
Kvien
80
 2.5 0 3 2.5 2  2 2.5  0 0 3 
Mengshoel
79
 3 0 3 3 0  2 1  0 0 3 
Riemsma
84,85
 3 0 3 3 0  2.5 0  0 0 3 
Scharloo
78
 2.5 0 2 2 0  0 0  0 0 3 
Tack
77
 3 2 3 3 2  2 0  0 0 3 
Tack
77
 3 2 3 3 1  1.5 0  0 0 3 
Uhlig
94
 1 0 0 0 0  0 0  0 0 1 
Wolfe
3,82,83
  2 0 3 1.5 1  2 1.5  0 0 2.5 
 
0 = Not reported/No evidence, 1 = Poor or limited evidence, 2 = Moderate evidence, 3 = Good evidence 
 
